Given the wide use of Acemetacin in AS and relative lack of clinical evidence on the selection of NSAIDs in the treatment of AS, the investigation on acemetacin treating AS is of great significance.

Objectives: Our study aims to investigate efficacy and safety of acemetacin in the treatment of AS.

Methods: Data on efficacy and safety is available in 1215 patients from the Chinese Ankylosing Spondylitis Imaging Cohort (CASPIC), which is collected through the Smart-phone SpondyloArthritis Management System (SpAMS)^[1]. Patients' self-assessments are completed online at baseline and every subsequent clinic visit. Physician-reported assessments, laboratory tests, and treatments were recorded by rheumatologists at every clinic visit.

Results: 1215 patients with AS were registered, of whom 992 were treated with acemetacin and 123 were treated with other NSAIDs. The results showed that total back pain and BASFI were significantly improved after three-month treatment of acemetacin, while comparing to other NSAIDs ($P=0.027$ and 0.015 , respectively). After six-month treatment, patients taking acemetacin showed greater improvement in PGA ($P=0.013$), total back pain ($P=0.049$), night back pain ($P=0.047$), BASFI ($P=0.042$), ASDAS ($P=0.007$) and CRP ($P=0.032$) compared to those taking other NSAIDs. During the follow-up periods, no serious adverse events were reported. Mild abnormal liver function occurred in nine patients (9/992) treated with acemetacin and in six patients treated with other NSAIDs (6/123). See Table 1 for details.

Conclusion: Acemetacin showed better efficacy and acceptable safety profile in the treatment of active ankylosing spondylitis comparing with other NSAIDs.

REFERENCES:

- Ji, X., et al., Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study. *BioMed research international*, 2019. 2019: p. 2171475.

Table 1. The comparison of two groups at 0, 3 and 6 months after treatment

	Baseline		3 months		6 months	
	95%CI	P	95%CI	P	95%CI	P
PGA	-0.13(-0.49, 0.24)	0.494	-0.28(-0.74, 0.18)	0.235	-0.59(-1.06, -0.11)	0.013*
Total back pain	-0.03(-0.37, 0.32)	0.889	-0.50(-0.94, -0.06)	0.027*	-0.44(-0.88, -0.002)	0.049*
Night back pain	0.01(-0.36, 0.38)	0.956	-0.30(-0.75, 0.16)	0.203	-0.46(-0.91, -0.006)	0.047*
BASFI	-0.30(-0.59, 0.004)	0.053	-0.55(-0.99, -0.11)	0.015*	-0.34(-0.67, -0.01)	0.042*
ASDAS	-0.10(-0.29, 0.08)	0.287	-0.15(-0.46, 0.16)	0.342	-0.41(-0.70, -0.11)	0.007*
CRP	-4.39(-8.87, 0.10)	0.055	0.91(-10.39, 12.21)	0.874	-7.86(-15.03, -0.68)	0.032*

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1958

POS0922

NON-STEROIDAL ANTI-INFLAMMATORY DRUG USE IS ASSOCIATED WITH DISEASE ACTIVITY AND REDUCED SIGNIFICANTLY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS; DATA FROM A REAL LIFE EXPERIENCE

E. Durak Ediboglu¹, D. Solmaz¹, G. Kabadayi¹, E. Otman Akat¹, H. Cinakli¹, G. Alp¹, E. Erpek¹, S. Guccenmez¹, M. Ozmen¹, S. Akar¹. ¹Izmir Katip Çelebi University, Rheumatology, Izmir, Turkey

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is only limited data regarding the concomitant use of NSAIDs during tumour necrosis factor inhibitor (TNFi) treatment.

Objectives: To evaluate longitudinal concomitant NSAIDs use with the TNFi treatment and the determinant of the ASAS-NSAID index in patients with axSpA.

Methods: In total 429 axSpA patients (253 [59%] male; 272 [63%] with AS and 157 [37%] with non-radiographic (nr)-axSpA) who have followed up one year were included in this observational study. The data regarding disease activity and serum CRP levels were collected on 12, 24 and 52nd week. At each visit NSAID usage, type, dosage and frequency were recorded in order to calculate ASAS-NSAID index. The longitudinal relationship between NSAID-index and other factors tested by using generalized estimating equations (GEE) which is a technique for longitudinal data analysis allowing the use of all available data even deviated from normality.

Results: At baseline 127/138 (92%) patients starting TNFi and 239/291 (82%) conventionally treated patients were using NSAID. Both the rate ($p=0.007$) and the median (IQR) ASAS-NSAID index were higher in biologic treatment group (100 [50] vs 70.8 [89.4]; $p<0.001$). During follow-up ASAS-NSAID index was decreased significantly in patients treated with TNFi (median 100 to 8.0; $p<0.001$), however ASAS-NSAID index was not changed in conventionally treated patients

($p=0.154$) (Figure 1). In univariate longitudinal analysis revealed that ASAS-NSAID index was significantly associated with BASDAI, ASDAS, BASFI scores and patient global assessment of disease activity, serum levels of CRP and education. We established two multivariable models (Table 1) to assess the associated factors/covariates with ASAS-NSAID index over time (one with ASDAS and the other BASDAI+CRP as disease activity index) and showed that BASDAI and patient global assessment of disease activity were independent determinants of NSAID dosage in biologic treated patients. However, in multivariate analysis there was no significant predictor for NSAID index in conventional treatment group.

Conclusion: Our results showed that NSAID prescription was significantly higher in axSpA patients who have TNFi indication. NSAID use was decreased significantly over time with TNFi and still independently determined by disease activity. However, it is stable in conventionally treated axSpA patients.

Table 1. The factors associated with ASAS-NSAID index in biologic treated patients

	Model 1			Model 2		
	B	95%CI	p	B	95% CI	p
BASFI	-0.55	-4.384; 4.275	0.980	0.943	-3.795; 5.682	0.696
BASMI	0.951	-1.511; 3.413	0.449	-0.098	-2.430; 2.234	0.934
PGA	0.535	0.210; 0.860	0.001	0.759	0.432; 1.086	0.000
CRP	-0.068	-0.220; 0.084	0.380			
BASDAI	5.718	2.487; 8.949	0.001			
ASDAI+CRP				1.771	-6.571; 10.113	0.677

PGA: Patient global assessment

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1961

POS0923

INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1

F. Van den Bosch¹, D. Poddubnyy^{2,3}, J. Stigler⁴, A. Ostor⁵, S. D'angelo⁶, V. Navarro-Compán⁷, I. H. Song⁴, T. Gao⁴, F. Ganz⁸, L. S. Gensler⁹. ¹Ghent University Hospital, Department of Rheumatology, Ghent, Belgium; ²Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Berlin, Germany; ³German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany; ⁴AbbVie Inc., Immunology, North Chicago, Illinois, United States of America; ⁵Cabrini Medical Center, Department of Rheumatology, Melbourne, Victoria, Australia; ⁶San Carlo Hospital of Potenza and "Madonna delle Grazie" Hospital of Matera, Rheumatology Institute of Lucania (IRel) – Rheumatology Department of Lucania, Potenza, Italy; ⁷University Hospital La Paz, IdiPaz, Department of Rheumatology, Madrid, Spain; ⁸AbbVie AG, Immunology, Baar, Switzerland; ⁹University of California, San Francisco, Rheumatology, San Francisco, California, United States of America

Background: Upadacitinib (UPA), an oral Janus kinase inhibitor, has demonstrated efficacy and safety through 14 weeks in the SELECT-AXIS 1 study in biologic disease-modifying antirheumatic drug-naïve patients with active ankylosing spondylitis (AS).¹